Meeting The Challenge

As a charter subscriber to The Scientist, I have noted an increasing bias toward the acceptance of traditional "ends-justify-the-means" pro-vivisection arguments in your publication. Albert M. Kligman's Commentary "Animal Rights (And Wrongs) [The Scientist, Oct. 29, 1990, page 16] underscores this perception by damning the animal protection movement with "faint praise," while conveying a surprising bewilderment of non-anthropocentric values. Kligman "demands" that animal advocates be willing t

Written byDonald Barnes
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Kligman "demands" that animal advocates be willing to openly debate with members of the scientific establishment, implying a reluctance within the pro-animal camp. Nothing could be further from the truth. It is increasingly difficult to find members of the active biomedical research community who will agree to such debates within our public institutions. As an ex-vivisector who spent 16 years coveting the same anthropocentric views espoused by Kligman before re-educating myself to both the ethical and scientific realities of vivisection, I am delighted by Kligman's challenge: "As for myself, I would welcome the chance to argue that we cannot forfeit animal testing if we wish to continue to improve the health and happiness of the human race."

I eagerly accept your challenge, Dr. Kligman--your place or mine?

DONALD J. BARNES
Director
National Anti-Vivisection Society
Washington, D.C.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies